Khan Najat
Officer at RXRX
- Sold, on record
- $1M
- Dollars the filings state
- Form 4 sales
- 5
- Latest Sep 8, 2026
- Form 144 notices
- 5
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- RXRXRECURSION PHARMACEUTICALS, INC.Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 144 notice RXRXNoticeDec 22, 2025 2025
Filed to sell 124,403 shares ($549k)
Khan Najat, Officer
10b5-1 planFiling
- 2 Form 4 sale RXRXRoutineDec 22, 2025 same day
Sold 124,403 shares at $4.41 ($549k)
Khan Najat, Chief R&D Commercial Officer
10b5-1 planSold 16.9% of holdings ($3.2M position)611,135 shares leftFollows a Form 144Filing
- 3 Form 144 notice RXRXNoticeMar 9, 2026 +77 days
Filed to sell 28,298 shares ($95k)
Khan Najat, Officer
10b5-1 planFiling
- 4 Form 4 sale RXRXRoutineMar 9, 2026 same day
Sold 28,298 shares at $3.35 ($95k)
Khan Najat, CEO and President
10b5-1 planSold 1.2% of holdings ($7.7M position)2.3M shares leftFollows a Form 144Filing
- 5 Form 144 notice RXRXNoticeJun 5, 2026 +88 days
Filed to sell 23,588 shares ($84k)
Khan Najat, Officer
10b5-1 plan0.6x usual sizeFiling
- 6 Form 4 sale RXRXRoutineJun 5, 2026 same day
Sold 23,588 shares at $3.58 ($84k)
Khan Najat, CEO and President
10b5-1 planSold 1.1% of holdings ($7.9M position)2.2M shares left0.6x usual sizeFollows a Form 144Filing
- 7 Form 144 notice RXRXNoticeSep 8, 2026 +95 days
Filed to sell 22,408 shares ($79k)
Khan Najat, Officer
10b5-1 plan0.7x usual sizeFiling
- 8 Form 4 sale RXRXRoutineSep 8, 2026 same day
Sold 22,408 shares at $3.52 ($79k)
Khan Najat, CEO and President
10b5-1 planSold 1.1% of holdings ($7.4M position)2.1M shares left0.7x usual sizeFollows a Form 144Filing
Every transaction
Loading transactions…
Sales and notices (10)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sep 8, 2026 | Sep 10, 2026 | RXRX | CEO and President | Form 4 sale | 22,408 | $79k | 1.1% | Routine | SEC |
| Sep 8, 2026 | Sep 8, 2026 | RXRX | Officer | Form 144 notice | 22,408 | $79k | Notice | SEC | |
| Jun 5, 2026 | Jun 5, 2026 | RXRX | CEO and President | Form 4 sale | 23,588 | $84k | 1.1% | Routine | SEC |
| Jun 5, 2026 | Jun 5, 2026 | RXRX | Officer | Form 144 notice | 23,588 | $84k | Notice | SEC | |
| Mar 9, 2026 | Mar 11, 2026 | RXRX | CEO and President | Form 4 sale | 28,298 | $95k | 1.2% | Routine | SEC |
| Mar 9, 2026 | Mar 9, 2026 | RXRX | Officer | Form 144 notice | 28,298 | $95k | Notice | SEC | |
| Dec 22, 2025 | Dec 29, 2025 | RXRX | Chief R&D Commercial Officer | Form 4 sale | 124,403 | $549k | 16.9% | Routine | SEC |
| Dec 22, 2025 | Dec 22, 2025 | RXRX | Officer | Form 144 notice | 124,403 | $549k | Notice | SEC | |
| Aug 18, 2025 | Aug 19, 2025 | RXRX | Chief R&D Commercial Officer | Form 4 sale | 36,599 | $202k | 5.2% | No plan | SEC |
| Aug 18, 2025 | Aug 18, 2025 | RXRX | Officer, Director | Form 144 notice | 36,599 | $202k | Notice | SEC |